Search for a trial

DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma (study 207503, DREAMM 7)

This study has been transitioned to CTIS with ID 2023-510537-28-00 check the CTIS register for the current data. Primary:To compare the efficacy of BM in combination with BOR/DEX with that of daratumumab in combination with BOR/DEX in participants…

A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

The anti-TIM-3 monoclonal antibody MBG453 is a novel immunotherapeutic agent with promising activity seen in AML and MDS. The purpose of the current study is to assess clinical effects of MBG453 in combination with azacitidine in adult subjects with…

Platelet analysis in patients with haematological diseases with increased risk of thrombosis and bleeding

To better treat and understand bleeding and thrombotic complications of these diseases and treatments, more insight is needed into the pathophysiology. WIth the findings of the current study we would like to increase knowledge on how platelets (and…

A Randomised Feasibility n-of-1 Trial of Weekly-Interval Red Cell Transfusion in myelodysplastic syndromes; Red blood cell transfusion schedule in myelodysplastic syndromes (REDDS): study 2

This protocol describes a two-part study to assess red blood cell (RBC) transfusion schedules in patients with transfusion-dependent myelodysplastic syndromes (MDS).The first part of the study is a pilot n-of-1 study to assess the feasibility of a…